WALTHAM, Mass.– Trinity Life Sciences, a leader in global life sciences commercialization solutions, introduces Trinity Contract Analytics, an offering that enhances U.S. payer and provider contract strategy decisions with cloud-based modeling, scenario planning and analytics. Though contracting is an incredibly vital piece of a life sciences company’s U.S. launch and access journey, constructing and evolving optimal contracting strategy is challenging. There are many scenarios and variables to evaluate when establishing the placement and targeting of contract value and investment.
Trinity Contract Analytics guides clients through U.S. pricing, contracting, provider economics and Gross-To-Net (GTN) decision-making through expertly curated insights, unlimited scenario analysis and accurate, comprehensive financial modeling. The new offering provides advisory services powered by Trinity CloudCast™, a cloud-based modeling and analytics tool.
With Trinity Contract Analytics, clients can:
- Establish confident contract and price change strategies with full understanding of the financial impact on payers, providers and all other stakeholders (wholesalers, Group Purchasing Organizations, etc.)
- Support contract negotiations and identify negotiating boundaries and breakeven points to mitigate the risk of accepting unfavorable and/or unprofitable contracts
- Protect market share from new or competing drugs and impact prescribing levels across an asset’s life cycle
- Enter a highly contracted market with precise pricing and contract strategies aligned to and customized for the relevant distribution channels and market segments
- Proactively and seamlessly incorporate competitive and market events—as well as U.S. policy changes—into contracting strategy
“In U.S. pharmaceutical contracting, there is immense complexity in evaluating the full impact of different proposal scenarios and decisions,” explained John Greenaway, Partner in the Evidence, Value, Access & Pricing (EVAP) practice at Trinity Life Sciences. “That complexity is exacerbated by downstream impacts which are often not intuitively considered in the context of contract decisions—a recent example is indirect exposure to the 2022 Inflation Reduction Act, or IRA, Medicare Prescription Drug Inflation Penalty Rebates. There are ripple effects into every deal analysis because these indirect costs can have as much, or more, impact on a product’s gross-to-net as the primary pricing or contract decisions actually being evaluated.”
“The core need is to quickly quantify the holistic impact of contracting decisions to optimize contract strategy, structures and terms to avoid making costly mistakes that cannot be rectified down the line—these are needs we built Trinity Contract Analytics to support,” added Monica Martin De Bustamante, Senior Partner & Head of the EVAP Practice at Trinity Life Sciences.
A webinar, Confident Contracting: Optimize and Accelerate Key Decisions with Tech-Enabled Impact Projections, on March 30 will discuss one of the most critical hurdles in developing and refining U.S. contract strategy and contract design: evaluating the holistic direct and indirect impacts of contract decisions across multiple scenarios at speed and with precision.
